Skip to contentA
Anika Therapeutics, Inc.
A
ANIKAnika Therapeutics, Inc. Q1 2014 · 10-Q
Revenue$34.01M$34.01M+123.1% vs Q1 2013 Net Income$15.03M$15.03M+389.9% vs Q1 2013 EPS Diluted$0.97$0.97+361.9% vs Q1 2013 Gross Profit$9,991,000+3.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anika Therapeutics, Inc. · CIK 898437 · Engraved from SEC EDGAR
Operating Cash Flow$13,596,657+124.0% Free Cash Flowderived$13,320,144+120.8% Margins · derivedGross margin29.4%−33.9 pt vs Q1 2013
Operating margin70.2%+37.3 pt vs Q1 2013
Net margin44.2%+24.1 pt vs Q1 2013
ended Mar 31, 2014 · filed May 5, 2014 · 35 d after period end